Comprehensive Clinical Study of Concurrent Chemotherapy Breathing IMRT Middle Part of Locally Advanced Esophageal Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The standard treatment of locally advanced type of mid-esophageal cancer is concurrent chemoradiation ther-apy (CRT). We evaluated the feasibility of chemotherapy with adding docetaxel to the classical basic regimens of cisplatin plus 5-fluorouracil (5-FU) and radiotherapy up to 70.2 Gy using dose escalations for esophageal cancer. It was possible to escalate radiation treatment dose up to 70.2 Gy by the respiratory-gated in-tensity-modulated radiotherapy (gated-IMRT) based on the 4DCT-simulation, with improving target coverage and normal tissue (ex., lung, heart, and spinal cord) sparing. This study suggested that the definitive chemo-radio-therapy with docetaxel, cisplatin, and 5-fluorouracil (i.e., DCF-R) and gating IMRT is tolerable and active in pa-tients with locally advanced mid-esophageal cancer (AEC).
Abstract
The standard treatment of locally advanced type of mid-esophageal cancer is concurrent chemoradiation ther-apy (CRT). We evaluated the feasibility of chemotherapy with adding docetaxel to the classical basic regimens of cisplatin plus 5-fluorouracil (5-FU) and radiotherapy up to 70.2 Gy using dose escalations for esophageal cancer. It was possible to escalate radiation treatment dose up to 70.2 Gy by the respiratory-gated in-tensity-modulated radiotherapy (gated-IMRT) based on the 4DCT-simulation, with improving target coverage and normal tissue (ex., lung, heart, and spinal cord) sparing. This study suggested that the definitive chemo-radio-therapy with docetaxel, cisplatin, and 5-fluorouracil (i.e., DCF-R) and gating IMRT is tolerable and active in pa-tients with locally advanced mid-esophageal cancer (AEC).
참고문헌 (35)
- Ulmer W, "3D photon superposition", convolution algorithm and its foundation on results of Monte Carlo calculations, 2005, pp.50(8), 1767~1790
- Geh JI, "Systematic overview of preoperative (neoadjuvant)chemo-radiotherapy trials in oesophageal cancer:evidence of a radiation and chemotherapy dose response", Radiother Oncol, 78(3), pp.236~234 (2006)
- Webb S, "A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density", Phys Med Biol, 38(6), pp.653~666 (1993)
- Gagliardi G, "Radiation dose-volume effects in the heart", Int J Radiat Oncol Biol Phys, 76, pp.S77~S85 (2010)
- Lyman JT, "Complication probability as assessed from dose-volume histograms", Radiat Res Suppl, 8, pp.S13~S19 (1985)
- Kutcher GJ, "Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method", Int J Radiat Oncol Biol Phys, 16(6), pp.1623~1630 (1989)
- Keall PJ, "The management of respiratory motion in radiation oncology report of AAPM Task Group 76", Med Phys, 33(10), pp.3874~3900 (2006)
- Cohen RJ, "Esophageal motion during radiotherapy: quantification and margin implications", Dis Esophagus, 23(6), pp.473~479 (2010)
- Gao XS, "Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma", Int J Radiat Oncol Biol Phys, 67(2), pp.389~396 (2007)
- Welsh J, "Esophageal cancer dose escalation using a simultaneous integrated boost technique", Int J Radiat Oncol Biol Phys, 82(1), pp.468~474 (2012)
- Prescribing, recording and reporting photon beam therapy, "International Commission on Radiation Units and Measurements", ICRU, ~, pp.ICRU report 62
- Keal P, "The clinical implementation of respiratory-gated intensity-modulated radiotherapy", Med Dosim, 31(2), pp.152~162 (2006)
- Wallis JW, "Three-dimensional display in nuclear medicine", Med Imag IEEE Trans, 8(2), pp.297~330 (1989)
- Wolf MC, "Curative treatment of esophageal carcinoma: Current options and future developments", Radiat Oncol, 6(1), pp.55~ (2011)
- Teoh AY, "Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: Results from a randomized controlled trial", Ann Oncol, 24(1), pp.165~171 (2012)
- Cunningham D, "Capecitabine and oxaliplatin for advanced esophagogastric cancer", N Engl J Med, 362(9), pp.858~859 (2010)
- Button MR, "Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy", Int J Radiat Oncol Biol Phys, 73(3), pp.818~823 (2009)
- Zhang Z, "Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy", Int J Radiat Oncol Biol Phys, 61(3), pp.656~664 (2005)
- Geh JI, "Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer:Evidence of a radiation and chemotherapy dose response", Radiother Oncol, 78(3), pp.236~244 (2005)
- Minsky BD, "INT 0123(Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy", J Clin Oncol, 20(5), pp.1167~1174 (2002)
- Gwynne S, "Oesophageal chemoradiotherapy in the UK: current practice and future directions", Clin Oncol (R Coll Radiol), 25(6), pp.368~377 (2013)
- Martel MK, "Fraction size and dose parameters related to the incidence of pericardial effusions", Int J Radiat Oncol Biol Phys, 40(1), pp.155~161 (1998)
- Hatakenaka M, "Acute cardiac impairment associated with concurrent chemoradiotherapy for esophageal cancer: Magnetic resonance evaluation", Int J Radiat Oncol Biol Phys, 83(1), pp.e67~e73 (2012)
- Bedenne L, "Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102", J Clin Oncol, 25(10), pp.1160~1168 (2007)
- Ishida K, "Phase II study of cisplatin and 5 fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: A Japan Esophageal Oncology Group (JEOG)", Japan Clinical Oncology Group trial (JCOG9516), 2004, pp.34(10), 615~619
- Ilson DH, "Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus", J Clin Oncol, 16(5), pp.1826~1834 (1998)
- Dunne AL, "Radiosensitization of colon cancer cell lines by docetaxel: Mechanisms of action", Oncol Res, 14(9), pp.447~454 (2004)
- Higuchi K, "A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501)", Radiother Oncol, 87(3), pp.398~404 (2008)
- Donahue JM, "Complete pathologic response after neoadjuvant chemo-radiotherapy for esophageal cancer is associated with enhanced survival", Ann Thorac Surg, 87(2), pp.398~398 (2009)
- Siegel R, "Cancer statistics 2012", Cancer J Clin, 62(1), pp.10~29 (2012)
- Orringer MB, "Transhiatal esophagectomy: clinical experience and refinements", Ann Surg, 230(3), pp.392~400 (1999)
- Chang AC, "Outcomes after transhiatal and transthoracic esophagectomy for cancer", Ann Thorac Surg, 85(2), pp.424~429 (2008)
- Suzuki A, "Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemo-radiotherapy", Cancer, 117(21), pp.4823~4833 (2011)
- Gillies RS, "Role of positron emission tomography–computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma", Br J Surg, 99(2), pp.239~245 (2012)
- Prins MJ, "The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study", Ann Oncol, 24(5), pp.1290~1297 (2013)
